Articles from FoRx Therapeutics AG

Basel, Switzerland – March 26, 2026 – FoRx Therapeutics, a clinical-stage biotechnology company developing precision anti-cancer therapeutics, today announced the presentation of the molecular structure, discovery, and preclinical data supporting the potential best-in-class profile of its PARG inhibitor, FORX-428, currently in Phase 1 development, at the American Chemical Society (ACS) Spring 2026 meeting in Atlanta.

Basel, Switzerland – December 18, 2025 – FoRx Therapeutics, a clinical-stage biotechnology company developing precision anti-cancer therapeutics, today announced the close of an insider-led USD 50 million (CHF 40 million) Series A financing. The funding will be used to advance Phase 1 clinical development of its lead drug candidate, FORX-428, a potential best-in-class PARG (poly (ADP-ribose) glycohydrolase) inhibitor designed to target and disrupt the DNA Damage Response (DDR) in advanced solid tumors.

Basel, Switzerland – August 11, 2025 – FoRx Therapeutics, a clinical-stage biotechnology company developing precision anti-cancer therapeutics, today announced the dosing of the first patient in a first-in-human clinical study of FORX-428, a novel PARG inhibitor designed to target and disrupt the DNA Damage Response (DDR) in advanced solid tumors.

FoRx Therapeutics AG, a Swiss-based company committed to discovering and developing innovative drugs targeting cancer-relevant DDR (DNA Damage Response) pathways, today announced that it has appointed Jens Würthner, MD PhD, as Chief Medical Officer. He is further strengthening FoRx Therapeutics’ existing management team with CEO Tarig Bashir, CSO Frank Zenke, and Head of Chemistry Ulrich Lücking.